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Methods: Between February 2002 and October 2004, we screened 201 
current and former smokers by bronchoscopy. In 99 subjects mucosal 
lesions were present and subsequently randomized for six months pla-
cebo or medication (results presented ASCO 2006). We retrospectively 
interviewed 182 volunteers who were current smokers at the time of 
recruitment. Subjects were interviewed by telephone by two students 
(RS and BP) using a standardised questionnaire with 35 questions 
concerning demographic data, smoking behaviour, perceived chance of 
getting lung cancer and motivation to quit smoking. 
Results: Of 182 subjects 103 were male, mean age 52 (24 -72), mean 
age of start smoking 15 yrs (3-30). Mean number of cigarettes/day at 
baseline was 27, volunteers who still smoked at the time of interview, 
smoked on average 22 cigarettes. Of the volunteers who were inter-
viewed 34 refused bronchoscopy and thus received no further informa-
tion on their health status, 63 were found to have no mucosal abnormal-
ity and 85 had some kind of premalignant lesion and were included in 
the trial. The number of volunteers who had quit smoking at the time 
of the interview was signiﬁcantly larger in the group with abnormali-
ties (x2 p< .05). There is no signiﬁcant relationship between subjective 
experience of the bronchoscopy and smoking behavior.
Conclusions: We found a signiﬁcant difference between number of 
quitters among smoking volunteers aware of presence of premalignant 
lesions in the bronchial mucosa compared to volunteers not eligible for 
this chemoprevention trial (without lesions or refusal of bronchoscopy).
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Rising incidence of bronchioloalveolar carcinoma and changes in 
the distribution of lung cancer cell types in China: experience of a 
teaching hospital
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Background: As a subtype of adenocarcinoma, bronchioloalveolar 
carcinoma of the lung (BAC) has a unique biological and clinical 
behavior. Several epidemiologic studies reported a signiﬁcant increase 
in the incidence of BAC. 
Methods. The authors retrospectively reviewed all of the pathologically 
conﬁrmed lung cancer cases from 1996-2005 at the PLA general hos-
pital, a large teaching hospital in China. Absolute number of all lung 
cancer cases and BAC cases, BAC as a percentage of all lung cancer 
and adenocarcinoma cases were analyzed. 
Results: During the study period, the number of histologically and/or 
cytologically conﬁrmed lung cancer cases in this hospital is 4706, 
among which 3623(77%) in men and 1083(23%) in women, with a 
male to female ratio of 3.3. The male-to-female ratio of all lung cancer 
cases showed a declining trend from 4.3:1 in 1996 to 3.0:1 in 2005. The 
male-to-female ratio of squamous cell carcinoma has fallen progres-
sively over the years, from 17.8:1 in 1996 to 6.7:1 in 2005. The ratio 
of non-BAC adenocarcinoma, BAC and small cell lung cancer didn’t 
show any increasing or declining trend. BAC has a minimum male-
to-female ratio of 1.4 contrasted to squamous cell carcinoma of 10.3, 
non-BAC adenocarcinoma of 2.3, small cell lung cancer of 3.6, large 
cell lung cancer of 3.7, all of which predominated by male. The mean 
age of all patients during the period 1996-2005 was 58.3 years (range, 
17-91 years) at the time of diagnosis. A decrease in the relative percent-
age of squamous cell carcinoma from 45.6% to 36.0% was noted. The 
relative percentage of BAC shows an increasing trend, from 10% in 
1996 to ~15% in 2004, except for an unexpected drop to 6.4% in 2005. 
At the same time, the percentage of non-BAC adenocarcinoma also 
steadily increased from 15.5% in 1996 to 28.6% in 2005. The rise in 
BAC contributes to the overall increase in adenocarcinoma. A total 
of 475 BAC cases represent 10.1% of all lung cancer cases. 7.7% of 
total lung cancer cases in men and 18.1% of total lung cancer cases in 
women were BAC. 
Conclusion: Both the absolute number and the percentage of BAC 
cases increased steadily over the investigation period. The emergence 
of BAC as a prominent type of lung cancer should stimulate novel ba-
sic and case-control clinical studies so that more reasonable treatment 
can be offered to treat the diseases.
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Lung cancer in patients under 50 years old
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Lung cancer in young patients is increasing in frequency.In 2005 in In-
stitute for Lung Diseases and TB were registered 1471 patients(pts)with 
lung cancer and 186 pts(12.65%)were under 50 years old.There were 
signiﬁcantly more male than female(70.9%:29.3%);mean age 45.8.The 
majority of them were smokers (76.1%).The diagnosis was established 
by ﬁberoptic bronchoscopy in 176(94.6%),percutaneus lung biopsy in 
5pts((2,6%)and in 5pts(2,6%) by lymphnode biopsy. In this group of 
patients the non-small-lung cancer(NSCLC) is found in
75,8%,compared to 24,2% for small cell lung cancer(SCLC).Unfor-
tunately 40,4% from them were with the metastatic disease.Surgical 
procedure was applied in 67pts (36,02%)chemotherapy was performed 
in 91(48,9%)pts,radiotherapy in 14(7,5%)pts.In 14pts(7,5%)the only 
treatment was symptomatic.
Conclusions: In the group of patients with lung cancer under 50 years 
old there were signiﬁcantly more male,smokers,with advanced stage 
lung cancer.Squamous cell carcinoma was the most frequent histologi-
cal type.
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The authors compare in their database including all patients with lung 
cancer since January 1990, the 160 patients included in 1990-5 (cohort 
A), and the 507 patients included in 2000-5 (cohort B).
The comparison shows, signiﬁcatively, an increase of number of lung 
cancer, an increase of women (A: 12 %, B: 25 %), of adenocarcinomas 
(A: 30 %, B: 53 %), of stage IV (A: 33 %, B: 44 %) and a reduction of 
squamous cell carcinomas (A: 41 %, B: 23 %), of stage IIIB ( A: 22 %, 
B: 12 %). Small cell lung cancer is stable (A: 11 %, B: 9 %).
Tobacco use is more important in cohort A (97%) than in B(92%). Age 
of both cohorts is the same (63.4 and 63.8 years)
In both cohorts, diagnosis is suspected in 77 % in front of symptoms.
The diagnosis is done in cohort A by endoscopy (70 %) and in cohort B 
by endoscopy (43%) and by CT-Transthoracic punction (20%).
Global survival is better in cohort B, 14.7 months, than in cohort A, 
10.7 months (p<0.002).
All TNM stages have a best survival in cohort B, but it is only sig-
niﬁcant for stage IV, PS 0-1 patients (B: 10.5 months, A: 6.7 months, 
p<0.0003) and for stage IIIB patients (B: 13.2 months, A: 9.3 months, 
p<0.0004). 
For the histology, for the gender, the difference are not signiﬁcant.
This best result seems due to a best selection of patients (Pet scan, RMI 
staging), to an increase of number of chemotherapy treatment in stage 
IV, in ﬁrst and second line, and to an use of third generation drugs. 
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(ECOG) studies using age of 60 years or older as a surrogate 
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Background: Women with advanced NSCLC tend to live longer than 
men for unclear reasons. A recent Southwest Oncology Group (SWOG) 
analysis of six trials of patients with advanced stage NSCLC (N=1334) 
again showed a survival advantage for women versus men, but interest-
ingly noted a cut-point for women around age 60, such that older wom-
en tended to live longer than younger women.(Albain IASLC-Chicago 
2006) Menopausal status was postulated as one explanation given the 
role of estrogen in lung cancer. To further explore this observation, we 
evaluated pooled data from two large ECOG trials, E1594 and E4599. 
Methods: E1594 randomized patients with advanced NSCLC to one of 
four platinum containing two-drug combination regimens, all of which 
had comparable efﬁcacy. E4599 randomized patients to carboplatin/pa-
clitaxel (one of the regimens on E1594) with or without bevacizumab. 
Because of confounding factors with bevacizumab, only the control 
arm is included in this analysis. Eligible patients from both E1594 
and the control arm of E4599 (N=1590) were divided into male and 
female cohorts and separated into age groups of < 60 or ≥ 60 years old. 
Survival was calculated separately for each cohort using the method of 
Kaplan-Meier. Known prognostic factors such as performance status, 
weight loss, and stage were also compared for each gender/age cohort 
using two-sided Fisher’s exact tests.
Results: 1590 eligible patients were included in this analysis consisting 
of 611 (38%) women and 979 (62%) men. 274 (45%) and 390 (40%) of 
women and men respectively were < 60 years old. A higher propor-
tion of those ≥ 60 were male (p=0.05), but there was no other statisti-
cally signiﬁcant differences in known prognostic factors between the 
4 gender/age cohorts. A statistically signiﬁcant difference in survival, 
however, was found. The median survival time (MST) for women ≥ 60 
years old was 11.6 months, versus 9.0 months for women < 60 (logrank 
p=.03). Men overall had lower survival than women, but no difference 
was seen for older men (MST of 7.4 months) versus men < 60 years 
old (MST of 8.3 months). Progression free survival (PFS) was also 
better for older women (4.7 months for those ≥ 60 years old versus 3.8 
months for younger women (logrank p =.009). Again no difference was 
seen for PFS for men of different ages, but men overall had shorter PFS 
than women.
Conclusions: As shown previously, women with advanced stage 
NSCLC live longer than men with the disease but the survival ad-
vantage is primarily for post-menopausal women at least 60 years of 
age. Known prognostic factors such as performance status, signiﬁcant 
weight loss, and stage cannot account for this difference. Men did 
not show a difference in survival by age. These data may indicate 
an important difference in lung cancer survival modiﬁed by meno-
pausal status. These data and the recent SWOG analysis make further 
investigation into the role of the estrogen pathway in lung cancer more 
compelling.
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Background: Histone methyltransferase (HMT) enzymes that methyl-
ate lysine residues of histone are involved in chromatin-mediated gene 
expression. The human homolog of the Drosophila gene Enhancer 
of Zeste 2 (EZH2) contains a highly conserved motif called the SET 
domain that required for the HMT activity. EZH2 has an important role 
in methylating histone H3 on Lys27, which leads to gene scilencing. 
Overexpression of the transcriptional repressor EZH2 was reported to 
be associated with the poor prognosis in various malignancies includ-
ing breast cancer and prostate cancer. In this study, we investigated the 
association between EZH2 polymorphisms and lung cancer risk. 
Materials and Methods: In a hospital-based study of 335 lung cancer 
patients and 335 age-, gender-matched healthy controls, 37 polymor-
phisms of EZH2 were examined. Of the 335 lung cancer patients, 189 
(56%) had adenocarcinomas, 77 (30%) had squamous cell carcinomas 
and 29 (9%) had small cell lung cancer. For a highly multiplexed SNP 
genotyping, the GoldenGate genotyping assay (Illumina Inc.) that 
combines an oligonucleotide ligation and allele-speciﬁc extension reac-
tion was performed. Statistical analyses were performed using logistic 
regression models with the adjustment for smoking status, pack-years 
and family history of cancer.
Results: All genotyped polymorphisms of EZH2 were in Hardy-Wein-
berg equilibrium in normal control population. When all age groups 
were analyzed together, one variant genotype of +19639A>G showed a 
signiﬁcant association with the reduced risk of lung cancer (AOR=0.72, 
